Phase 4
N=80
Improving PET Image Quality and Quantification by Using Motion Correction, Parametric Imaging and MAP Reconstruction
Brain Imaging · Whole Body Imaging
Bottom Line
View on ClinicalTrials.gov: NCT04417998 ↗Enrolled (actual)
80
Serious AEs
0.0%
Results posted
Jan 2025
Primary outcome: Primary: Motion Correction — 57.4; 13.9 percentage of voxels
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 4
- Interventions
- 18F-FDG (Drug); 18F-AV1451 (Drug); Siemens E7 Reconstruction Tool (Device)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Mayo Clinic
- Primary completion
- Dec 2023
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Motion Correction |
57.4; 13.9 | — |
| PRIMARY Parametric Imaging |
0.0311 | — |
| PRIMARY Map Reconstruction |
17; 16; 37; 48 | — |
Summary
The purpose of this study is to assess the effectiveness of new software available on a new PET/CT scanner in the Molecular Imaging Research PET/CT Facility. Further, the study aims to evaluate the data acquisition and image processing workflow.
Eligibility Criteria
Inclusion Criteria
- 18 years of age or older
- Subjects who are able and willing to sign the informed consent
- Subjects who are able to follow verbal commands
- A negative urine pregnancy test within 48 hours prior to PET imaging procedures in females of childbearing potential
- Subjects who are scheduled for a PET/CT study under Mayo Clinic Rochester IRB research protocol 08-005553 (Aim 1 cohort only)
- A positive 18F-FDG oncology PET/CT exam in the last six months (Aim 2 cohort only)
Exclusion Criteria
- Patients who are unable to lay still for an additional 15 minutes (for Aim 1 cohort)
- Patients who are unable to lay still for 90 min for 18F-FDG scans or 100 min for 18F-AV1451 scans (for Aim 2 cohort)
- Patients who cannot follow the prep instructions
Data sourced from ClinicalTrials.gov (NCT04417998). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.